Global Dental Implant Market Report 2024-2032 Featuring Strategic Analysis of Danaher, Dentsply Sirona, Institut Straumann, Zimmer Biomet, and Kyocera Among Others
May 31, 2024 04:45 ET
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Global Dental Implant Market Report by Material Types, Design, Types, End-Users, Regions and Company Analysis 2024-2032" report has been added to ...
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
May 30, 2024 18:01 ET
|
Novartis Pharma AG
Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s...
Verana Health Announces Launch of Qdata® Uveitic Macular Edema Module
May 30, 2024 09:00 ET
|
Verana Health, Inc.
Expansive, high-quality real-world dataset of more than 152,000 de-identified patients utilizes electronic health record data to confirm the diagnosis and better understand the outcomes of patients...
ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society
May 30, 2024 06:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024
Dermatology Specialists of Florida to Open New Office in Niceville Florida
May 29, 2024 18:00 ET
|
Dermatology Specialists
Panama City, May 29, 2024 (GLOBE NEWSWIRE) -- Panama City, Florida - Dermatology Specialists of Florida is excited to announce the opening of a new clinic in Niceville, Florida, bringing...
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
May 29, 2024 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
May 28, 2024 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in Obstructive Sleep Apnea
May 23, 2024 09:50 ET
|
Apnimed, Inc.
Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in Obstructive Sleep Apnea
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
May 22, 2024 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to announce its new division, Nexalin America, has been selected...
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
May 22, 2024 08:00 ET
|
Avadel Pharmaceuticals plc
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in...